

# BRAIN TUMOR ANALYSIS REPORT

## AI-Powered Segmentation and Clinical Assessment

### Patient Information

| Field       | Value                                     |
|-------------|---|
| Report Date | 2025-09-19T11:35:28.436801                |
| Case ID     | case_fe8d688e-30b5-4668-87a1-10fabcd52985 |

# AI-GENERATED CLINICAL REPORT

## EXECUTIVE SUMMARY

This case demonstrates a large right-sided central brain tumor with moderate enhancement and significant peritumoral edema. The tumor exhibits minimal necrosis and a heterogeneous composition, consistent with a high-grade glioma. Quantitative analysis indicates a very large tumor burden with substantial surrounding edema, warranting urgent clinical evaluation and multidisciplinary management.

## TUMOR MORPHOLOGY AND LOCATION

- Location: Right hemisphere, central brain region
- Size Classification: Very large ( $>15\text{ cm}^3$ )
- Maximum Diameter: 62.0 mm
- Anatomical Considerations: The central location in the right hemisphere may be associated with potential involvement of critical motor and sensory pathways, necessitating careful functional assessment and surgical planning if indicated.

## QUANTITATIVE ANALYSIS

- Total Tumor Volume:  $52.92\text{ cm}^3$
- Tumor Core Volume:  $11.12\text{ cm}^3$
- Enhancing Component:  $10.86\text{ cm}^3$  (20.5%)
- Necrotic Component:  $0.26\text{ cm}^3$  (0.5%)
- Edematous Component:  $41.80\text{ cm}^3$  (79.0%)

## ENHANCEMENT CHARACTERISTICS

- Enhancement Pattern: Moderate (10–30%)
- Enhancement Intensity: Mean 520.73, Maximum 1146.00
- Clinical Significance: Moderate enhancement suggests active tumor proliferation with possible blood-brain barrier disruption. The presence of enhancement is consistent with malignant glioma, particularly anaplastic astrocytoma or glioblastoma.

## TISSUE COMPOSITION ANALYSIS

| Tissue Component | Presence | Clinical Interpretation |

|--||

| Enhancing Tissue | Present | Indicates viable tumor tissue with active proliferation and vascular permeability. |

| Necrotic Core | Present | Minimal necrosis (0.5%) is consistent with high-grade glioma; may reflect treatment response or tumor biology. |

| Peritumoral Edema | Present | Extensive edema (79%) reflects significant mass effect and inflammatory response, contributing to neurological symptoms. |

## CLINICAL ASSESSMENT

- Tumor Grade Indicators:

- Moderate enhancement
- Extensive edema
- Minimal necrosis
- Large tumor volume

These features are consistent with a high-grade glioma, possibly anaplastic astrocytoma or glioblastoma, though definitive grading requires histopathological correlation.

- Differential Diagnosis:

- High-grade glioma (anaplastic astrocytoma or glioblastoma)
- Malignant meningioma (if enhancing margins are irregular)
- Metastatic lesion (if patient history supports)

- Prognosis Indicators:

- Large tumor volume and extensive edema suggest aggressive behavior.
- Minimal necrosis may indicate active tumor rather than treatment-related change.
- Moderate enhancement is consistent with high-grade malignancy.

## RECOMMENDATIONS

1. Immediate Actions:

- Urgent neurosurgical consultation for potential biopsy or resection.
- Neurological evaluation for symptom management and functional assessment.

2. Additional Imaging:

- Contrast-enhanced MRI with diffusion-weighted imaging (DWI) and perfusion imaging to further characterize tumor vascularity and cellularity.
- Consider MRI spectroscopy (MRS) for metabolic characterization.

3. Multidisciplinary Review:

- Involvement of neuro-oncology, radiation oncology, and neuropathology teams for staging and treatment planning.

#### 4. Follow-up Protocol:

- Repeat MRI within 2–4 weeks post-treatment initiation.
- Functional MRI (fMRI) and DTI if surgical resection is planned.

#### 5. Treatment Considerations:

- Consider surgical resection if feasible and safe.
- Initiate radiation therapy and chemotherapy (e.g., temozolomide) in accordance with standard protocols for high-grade gliomas.
- Monitor for signs of increased intracranial pressure due to edema.

## TECHNICAL NOTES

- Image Quality: Adequate for diagnostic interpretation
- Segmentation Confidence: High automated detection accuracy
- Limitations: Standard limitations of MRI-based analysis include potential overestimation of edema and variability in tumor core definition; histopathological correlation remains essential for definitive diagnosis.

Report Generated: September 19, 2025 at 11:35 AM


System: AI-Assisted Brain Tumor Analysis Platform

Case ID: case\_fe8d688e-30b5-4668-87a1-10fabcd52985

# SEGMENTATION VISUALIZATIONS


## FLAIR Segmentation Overlay

FLAIR with Segmentation Overlay




## T1CE Segmentation Overlay

### T1CE with Segmentation Overlay





### T2 Segmentation Overlay

#### T2 with Segmentation Overlay




### 3D Volume Analysis

3D Tumor Segmentation Views




# QUANTITATIVE ANALYSIS


Tumor Component Distribution




Component Volume Comparison



Tissue Composition Percentages



Tumor Size Classification  
(Current: 52.92 cm³)





Clinical Summary Table

| Parameter           | Value         | Clinical Significance          |
|---------------------|---------------|--------------------------------|
| Total Volume        | 52.92 cm³     | very_large (>15 cmÂ³)          |
| Maximum Diameter    | 62.0 mm       | Surgical planning reference    |
| Enhancement         | 20.5%         | moderate (10-30%)              |
| Necrosis            | 0.5%          | minimal (<10%)                 |
| Location            | right central | Functional considerations      |
| Enhancement Present | yes           | Blood-brain barrier disruption |
| Necrosis Present    | yes           | Tissue viability indicator     |
| Edema Present       | yes           | Peritumoral involvement        |

## IMPORTANT DISCLAIMERS

- This report is generated using artificial intelligence algorithms for automated brain tumor segmentation and analysis.
- The AI model used for report generation is designed to assist healthcare professionals but does not replace clinical judgment.
- All quantitative measurements and assessments should be validated by qualified radiologists and medical professionals.
- Treatment decisions should not be based solely on this automated analysis.
- This system is intended for research and educational purposes and to support clinical decision-making.
- Report generated on September 19, 2025 at 11:35 AM using Qwen/Qwen3-Coder-30B-A3B-Instruct.